Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial

British Journal of Cancer

Volumn 78, Issue 5, 1998, Pages 572-578

  Decensi, A ^a,b   Robertson, C ^a   Rotmensz, N ^a   Severi, G ^a   Maisonneuve, P ^a   Sacchini, V ^a   Boyle, P ^a   Costa, A ^a   Veronesi, U ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast neoplasm; Chemoprevention; Cholesterol; Oestrogen replacement therapy; Tamoxifen

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031903684     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.542     Document Type: Article

References (46)

1. Assikis VJ, Neven P, Jordan VC and Vergote I (1996) A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A: 1464-1476
2. Belchetz PE (1994) Hormonal treatment of postmenopausal women. N Engl J Med 330: 1062-1071
3. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG and Singh R (1996) The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol 7: 671-675
4. Chetkowsky RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP and Judd HL (1986) Biologic effects of transdermal estradiol. N Engl J Med 314: 1615-1620
5. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047-1059
6. Colvin Jr PL, Auerbach BJ, Koritnik DR, Hazzard WR and Applebaum-Bowden D (1990) Differential effects of oral estrone versus 17 beta-estradiol on lipoproteins in postmenopausal women. J Clin Endocrinol Metab 70: 1568-1573
7. Costantino JP, Kuller LH, Ives DG, Fisher B and Dignam J (1997) Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89: 776-782
8. Early Breast Cancer Trialists' Collaborative Group (1992) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
9. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickely HL and Ketner M (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumours. N Engl J Med 320: 479-484
10. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537
11. Friedewald WT, Levy RI and Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
12. Gallo MA and Kaufman D (1997) Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 24 (suppl. 1): s171-s180
13. Gillum RF, Ingram DD and Makuc DM (1993) White blood cell count, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 125: 855-863
14. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE and Hennekens CH (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335: 453-461
15. Grodstein F, Stanpfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH and Speizer FE (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769-1775
16. Handin RI (1996) Platelets and coronary artery disease. N Engl J Med 334: 1126-1127
17. Holme I (1990) An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 82: 1916-1924
18. Jaiyesimi IA, Buzdar AU, Decker DA and Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529
19. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M and Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488-1491
20. Katzenellenbogen BS (1996) Estrogen receptors: bioactivities and interactions with cell signalling pathways. Biol Reprod 54: 287-293
21. Kinosian B, Glick H and Garland G (1994) Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 121: 641-647
22. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP and DeMets DL (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327-1332
23. Love RR, Cameron L, Connell BL and Leventhal H (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151: 1842-1847
24. Lukac J, Kusic Z, Kordic D, Koncar M and Bolanca A (1994) Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 29: 279-285
25. McDonald CC, Alexander FE, White W, Forrest AP and Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 311: 977-980
26. Nachtigall LE (1995) Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Am J Obstet Gynecol 173: 993-997
27. Nayfield S (1995) Tamoxifen's role in chemoprevention of breast cancer. An update. J Cell Biochem suppl. 22: 42-50
28. Newcomb PA and Storer BE (1995) Postmenopausal hormone use and risk of large bowel cancer. J Natl Cancer Inst 87: 1067-1071
29. Powles TJ, Hickish T, Casey S and O'Brien M (1993) Hormone replacement after breast cancer. Lancet 342: 60-61
30. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA and Davey JB (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82
31. Powles TJ, Hickish T, Kanis JA, Tidy A and Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorpiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84
32. Riggs B and Melton L (1992) The prevention of osteoporosis. N Engl J Med 327: 620-627
33. Rosemberg L, Hennekens CHE, Rosner B, Belanger C, Rothman KJ and Speizer FE (1981) Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 139: 47-51
34. Roy JA, Sawka CA and Pritchard KI (1996) Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? J Clin Oncol 14: 997-1006
35. Rutqvist LE, Mattson A for the Stockholm Breast Cancer Study Group (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85: 1398-1406
36. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T and Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87: 645-651
37. Slowinska-Srzednicka J, Zgliczynski S, Jeske W, Stopinska-Gluszak U, Srzednicki M, Brzezinska A, Zgliczynski W and Sadowski Z (1992). Transdermal 17 beta-estradiol combined with oral progestagen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest 15: 533-538
38. Smigel K (1998) Breast cancer prevention trial shows major benefit, some risk. J Natl Cancer Inst 90: 647-648
39. Smith GD, Song F and Sheldon TA (1993) Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 306: 1367-1373
40. Thaulow E, Erikssen J, Sandvik L, Stormorken H and Cohn PF (1991) Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84: 613-617
41. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273: 199-208
42. Van Erpecum KJ, Van Berge Hengouwen GP, Verschoor GP, Verschoor L, Stoelwinder B and Willekens FLH (1991) Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 100: 482-488
43. Walsh BW, Li H and Sacks FM (1994) Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35: 2083-2093
44. Weissberger AJ, Ho KK and Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72: 374-381
45. Yang NN, Venugopalan M, Hardikar S and Glasebrook A (1996) Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene. Science 273: 1222-1225,
46. and comments in Pennisi E (1996) Drug's link to genes reveals estrogen's many sides. Science 273: 1171